ChitogenX Inc. (CHGX.CN)
| Previous Close | 0.0300 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 12,742 |
| Market Cap | 2.364M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0600 |
| Earnings Date | May 29, 2024 - Jun 03, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupCHITOGENX ANNOUNCES EXECUTIVE LEADERSHIP CHANGES
ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that Philippe Deschamps, Chief Executive Officer, has decided to step down as CEO for personal reasons and has resigned from the Board of directors, effective February 28, 2024. Mr. Pierre Laurin who currently serves as Chairman of the Board of directors, will act as interim CEO while the Board of directors reviews potential alternatives to fill the position p
CNW GroupCHITOGENX REPORTS THIRD QUARTER 2024 RESULTS
ChitogenX Inc., (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today reported its financial results and highlights for the third quarter of fiscal year 2024 ended on October 31, 2023.
CNW GroupCHITOGENX DEMONSTRATES ORTHO-R EFFICACY AND OSTEOARTHRITIS PROTECTION IN LARGE ANIMAL MENISCAL REPAIR STUDY
ChitogenX Inc. (CSE: CHGX) (OTCQB: CHNXF) ("ChitogenX" or the "Company"), a clinical-stage regenerative medicine company, today announced that ORTHO-R, its proprietary chitosan/PRP based biopolymer matrix, has successfully demonstrated protection from joint degeneration post meniscal repair surgery in a large animal study.
